Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
RIGL Stock Chart & Stats
$30.69
-$0.99(-5.79%)
At close: 4:00 PM EST
$30.69
-$0.99(-5.79%)
Day’s Range― - ―
52-Week Range$13.57 - $43.72
Previous CloseN/A
Volume99.93K
Average Volume (3M)606.75K
Market Cap
$542.96M
Enterprise Value$292.84M
Total Cash (Recent Filing)$108.38M
Total Debt (Recent Filing)$61.04M
Price to Earnings (P/E)5.7
Beta2.18
Next Earnings
Nov 06, 2025EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.28
Shares Outstanding17,937,340
10 Day Avg. Volume498,058
30 Day Avg. Volume606,751
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda2.68
Forecast
1Y Price Target
$42.50Price Target Upside38.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe first patient has been enrolled into the dose expansion phase of the Phase 1b R289 study, marking an important step in R289's development.
Global ExpansionTavalisse’s expanding global footprint and growing commercial portfolio supports access.
Revenue GrowthTavalisse delivers record growth and contributes to a strong total revenue performance.
Bears Say
Clinical Trial RisksFactors that could impede reaching the price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding.
Rigel News
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $13.57 and its highest was $43.72 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $542.96M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 06, 2025 which is in 13 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 05, 2025. The company reported $3.28 earnings per share for the quarter, beating the consensus estimate of $2.58 by $0.7.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.9.
How many shares outstanding does Rigel have?
Rigel has 17,937,340 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of $3.28 in its last earnings report, beating expectations of $2.58. Following the earnings report the stock price went up 22.979%.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in RIGL
Rigel Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.50 (38.48% Upside)
$42.50 (38.48% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 21.2%
Last 30 Days ▲ 21.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.52%
12-Months-Change
Fundamentals
Return on Equity
376.09%
Trailing 12-Months
Asset Growth
61.00%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was overwhelmingly positive, highlighting significant sales growth across all products, increased revenue guidance, strong financial performance, and successful market expansion strategies. While there was a minor reevaluation in patient responder data, it did not significantly detract from the overall positive performance and outlook for the company.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$42.50
▲(38.48% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Verastem
―
RegenXBio
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―
Ownership Overview
2.60% Insiders
27.81% Mutual Funds
0.28% Other Institutional Investors
54.35% Public Companies and
Individual Investors